# Tong Maomeng

> Tong Maomeng is a Series A investor at INCE Capital backing Biopharma and Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [INCE Capital](https://shizune.co/investors/profile/ince-capital)
- Total investments: 1
- Last investment: Nov 2025
- Lead investor: 0%
- Last updated: Aug 2026

Tong Maomeng is a Series A investor at INCE Capital focused on Biopharma and Biotechnology. Tong Maomeng is the Executive Director of Yingce Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Brise Pharma | Brise Pharma operates in the scientific research and technical service industry. | $28.1M | Series A | Nov 11, 2025 |  |

1 of 1 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [Beijing Medical and Health Industry Investment Fund](https://shizune.co/investors/profile/beijing-medical-and-health-industry-investment-fund) — VC Fund, 1 deal together
- [Guanghua Wutong Fund](https://shizune.co/investors/profile/guanghua-wutong-fund) — VC Fund, 1 deal together
- [Prox Ventures](https://shizune.co/investors/profile/prox-ventures) — VC Fund, 1 deal together
- [Shunxi Fund](https://shizune.co/investors/profile/shunxi-fund) — VC Fund, 1 deal together

## About INCE Capital

VC Fund · Shanghai, China

INCE Capital is a new fund that will invest in early-stage consumer-related technology companies in China.

3 contacts available at INCE Capital.

| Name | Title | Profile |
| --- | --- | --- |
| JP Gan | Founding Partner | https://shizune.co/investors/profile/jp-gan |
| Steven Hu | Founding Partner | https://shizune.co/investors/profile/steven-hu |
| Tong Maomeng | Executive Director | https://shizune.co/investors/profile/tong-maomeng |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Tong Maomeng invest in?

Tong Maomeng invests primarily in Biopharma, Biotechnology and Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Tong Maomeng last invest?

The most recent investment recorded for Tong Maomeng closed in Nov 2025. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co